EU approval - New GM crops accepted by default decision

被引：0
|
作者：
Walter, Patrick
机构：
来源：
CHEMISTRY & INDUSTRY | 2007年 / 21期
关键词：
D O I：
暂无
中图分类号：
O69 [应用化学];
学科分类号：
081704 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [41] GM directive deficiencies in the European Union - The current framework for regulating GM crops in the EU weakens the precautionary principle as a policy tool
    Morris, Shane H.
    Spillane, Charles
    EMBO REPORTS, 2008, 9 (06) : 500 - 504
  • [42] On the asynchronous approvals of GM crops: Potential market impacts of a trade disruption of EU soy imports
    Henseler, Martin
    Piot-Lepetit, Isabelle
    Ferrari, Emanuele
    Gonzalez Mellado, Aida
    Banse, Martin
    Grethe, Harald
    Parisi, Claudia
    Helaine, Sophie
    FOOD POLICY, 2013, 41 : 166 - 176
  • [43] TRANSACTIONAL BY DEFAULT: EU-TURKEY RELATIONS IN SEARCH OF A NEW RATIONALE
    Janning, Josef
    TURKISH POLICY QUARTERLY, 2018, 17 (01): : 57 - 65
  • [44] Genetically modified (GM) crops: milestones and new advances in crop improvement
    Ayushi Kamthan
    Abira Chaudhuri
    Mohan Kamthan
    Asis Datta
    Theoretical and Applied Genetics, 2016, 129 : 1639 - 1655
  • [45] Genetically modified (GM) crops: milestones and new advances in crop improvement
    Kamthan, Ayushi
    Chaudhuri, Abira
    Kamthan, Mohan
    Datta, Asis
    THEORETICAL AND APPLIED GENETICS, 2016, 129 (09) : 1639 - 1655
  • [46] The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars
    Niazi, Sarfaraz K.
    PHARMACEUTICALS, 2023, 16 (11)
  • [47] Impact of the US Accelerated Approval for New Anticancer Drugs on Time to Verification of Benefit and Regulatory Approval in the EU and Japan
    Akira Ito
    Mamoru Narukawa
    Therapeutic Innovation & Regulatory Science, 2024, 58 : 136 - 142
  • [48] Impact of the US Accelerated Approval for New Anticancer Drugs on Time to Verification of Benefit and Regulatory Approval in the EU and Japan
    Ito, Akira
    Narukawa, Mamoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (01) : 136 - 142
  • [49] New type of polyvalent immunoglobulin Privigen® obtains EMEA-approval for the EU
    Lotichius, Peer
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2008, 35 (04) : 330 - 330
  • [50] The meta-governance of risk and new technologies:: GM crops and mobile telephones
    Walls, J
    O'Riordan, T
    Horlick-Jones, T
    Niewöhner, J
    JOURNAL OF RISK RESEARCH, 2005, 8 (7-8) : 635 - 661
12345